The company's revenue declined by 25% YoY, and net losses increased by 10% due to higher R&D expenses. Additionally, there are significant risks related to regulatory approvals, NASDAQ compliance, and financial stability. No new partnerships or positive strategic updates were announced. The lack of positive catalysts and increased uncertainties suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.